Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 108Magnetic Resonance Spectroscopy 77Biopsy 76pembrolizumab 59Cyclophosphamide 49fludarabine 40Carboplatin 25Nivolumab 24Cetuximab 23venetoclax 21Radiotherapy 21Cisplatin 21Bevacizumab 20atezolizumab 18X-Rays 18Radiation 17Ipilimumab 17fludarabine phosphate 16Fluorouracil 16Gemcitabine 15Temozolomide 14Paclitaxel 14Leucovorin 14Irinotecan 14Cytarabine 14durvalumab 13Pemetrexed 13Azacitidine 13Oxaliplatin 12CTLA-4 Antigen 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Nuclear Medicine Department, Hospital × 30 days × Clear all
NCT06287944 2026-05-18

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1 Recruiting
15 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡